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Abstract  
Hypohidrotic ectodermal dysplasias (HED) are hereditary differentiation disorders of multiple 
ectodermal structures including the mammary gland. The X-linked form of HED (XLHED) is 
caused by a lack of the secreted signaling molecule ectodysplasin A1 (EDA1) which is 
encoded by the gene EDA and belongs to the tumor necrosis factor (TNF) superfamily. 
Although male patients (hemizygous) are usually more severely affected by XLHED, 
heterozygous female carriers of an EDA mutation may also suffer from a variety of 
symptoms, in particular from abnormal development of their breasts. In Tabby mice, a well-
studied animal model of XLHED, EDA1 is absent. We investigated the effects of prenatal 
administration of Fc-EDA, a recombinant EDA1 replacement protein, on mammary gland 
development in female Tabby mice. Intra-amniotic delivery of Fc-EDA to fetal animals 
resulted later in improved breastfeeding and thus promoted the growth of their offspring. In 
detail, such treatment led to a normalization of the nipple shape (protrusion, tapering) that 
facilitated sucking. Mammary glands of treated female Tabby mice also showed internal 
changes, including enhanced branching morphogenesis and ductal elongation. Our findings 
indicate that EDA receptor stimulation during development has a stable impact on later 
stages of mammary gland differentiation, including lactation, but also show that intra-amniotic 
administration of an EDA1 replacement protein to fetal Tabby mice partially corrects the 
mammary gland phenotype in female adult animals. 
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Introduction 
 
Ectodermal dysplasias are a group of rare and heterogeneous hereditary disorders, 
characterized by impaired development of multiple ectodermal structures such as hair, nails, 
teeth, and various eccrine glands including sweat and mammary glands [1, 2]. X-linked 
hypohidrotic ectodermal dysplasia (XLHED; Christ-Siemens-Touraine syndrome; #MIM 
305100), the most frequent of the numerous ectodermal dysplasias, is caused by mutations 
in the gene EDA (located on chromosome Xq12–q13.1), which encodes ectodysplasin A1 
(EDA1, hereinafter EDA), a member of the tumor necrosis factor ligands family. XLHED is a 
rare disorder with an incidence between 1:30000 and 1:100000. Mutations in the genes 
coding for the EDA receptor (EDAR on chromosome 2q11–q13) and its associated death 
domain-containing adaptor protein (EDARADD on chromosome 1q42–q43) result in 
autosomal dominant (#MIM 129490) and autosomal recessive (#MIM 224900) forms of HED 
[3]. The proteins encoded by these three genes are all involved in the common nuclear factor 
(NF)-κB signaling pathway which is fundamental for normal ectodermal development and a 
key mediator of EDA signaling [4]. A few potential target genes of the EDA-NF-κB pathway 
have been identified. These include CCND1 [5], DKK4 [6], PTHrP, WNT10a, and WNT10b 
as well as the EGF family ligand genes AREG and EPGN [7]. Moreover, EDA has been 
identified as a factor influencing different steps of mammary gland morphogenesis through 
activation of NF-κB signaling in the epithelium [7]. Mutations in EDA, EDAR and EDARADD 
lead to similar phenotypes. Male XLHED patients (hemizygous for an EDA mutation) are 
more severely affected than heterozygous female carriers who present with variable 
symptoms such as missing and/or abnormal teeth, hypotrichosis and a reduced ability to 
sweat (hypohidrosis) [8-10]. Many affected women also suffer from an abnormal 
development of their breasts. Beyond the individual cosmetic relevance, this can severely 
limit their breastfeeding ability [11]. Various case reports have documented a disruption of 
breast development secondary to mutations in one of the genes of the EDA signaling 
pathway in humans [12-16].  
Development of the mammary gland starts in the fetus. Sequential and reciprocal signals 
between the epithelium and surrounding mesenchyme implement the outgrowth of a small 
duct into the dermal mesenchyme and formation of the nipple. During puberty the cyclical 
production of hormones accelerates ductal outgrowth and branching. Proliferation and 
maturation of the alveolar compartment occurs only during pregnancy. At term, the breasts 
reach maturity and produce milk to feed the young [17]. 
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Tabby mice represent a well-studied animal model of XLHED [18-20] in which the EDA 
protein is absent due to a deletion of exon 1 [8]. Prenatal intravenous administration of Fc-
EDA, a recombinant fusion protein consisting of the receptor-binding domain of EDA and the 
Fc part of immunoglobulin G1, to pregnant dams corrected the developmental abnormalities 
in the offspring [21]. This treatment strategy, however, exposes the mother to high serum 
levels of an exogenous molecule and may be suboptimal for achieving reproducible drug 
concentrations in human fetuses. Therefore, fetal Tabby mice were treated by intra-amniotic 
administration of Fc-EDA, which resulted in a complete reversion of the XLHED phenotype 
[22] including normalized eye opening, retro-auricular and guard hair growth, and regular 
eccrine sweat gland function at the paws. In addition, size and shape of the molars 
resembled those of wild-type mice [22].  
Here we report an improvement of the breastfeeding ability of female Tabby mice following 
prenatal treatment with Fc-EDA. Intra-amniotic administration of this replacement protein to 
fetuses partially corrected mammary gland development including the nipple shape in female 
animals, while epithelial function was not completely restored. 
 
Material and methods 
 
Animal model and treatment 
C57BL/6 wild-type mice (Charles River, Sulzfeld, Germany), white-bellied agouti B6CBAa 
Aw-J/A-EdaTa/J Tabby mice (000314; Jackson Laboratory, Bar Harbor, USA) and 
appropriate control mice were housed in individually ventilated cages under standard 
conditions with a light/dark cycle of 12 hours and free access to standard chow and tap 
water. All experimental procedures on animals were conducted in accordance with the 
German regulations and legal requirements and had been approved by the local government 
authorities. Intra-amniotic injections were performed as described previously [22]. In short, 
time-mated pregnant mice on gestational day 15 (E15) were anesthetized with isoflurane 
(2%). For perioperative analgesia, metamizole (100 µl, 50 mg/ml) was administered 
subcutaneously. The abdominal cavity was opened by midline laparotomy and both uterine 
horns were exposed completely. Fc-EDA was injected into the amniotic sacs of individual 
fetuses at doses of 100 µg/g fetal body weight (16 µl of Fc-EDA at 2.2 mg/ml, assuming a 
fetal weight of approximately 0.35 g) using glass syringes with 33 gauge needles (Hamilton 
Robotics, Bonaduz, Switzerland). The uterus was then placed back in the abdomen, the 
abdominal wall was closed by continuous suture of the peritoneal layer and interrupted 
stitches of the skin, and mice were allowed to recover in a pre-warmed cage.  
All treated fetuses survived the injection procedure and were born without complications. For 
breastfeeding studies untreated and prenatally Fc-EDA-treated Tabby females were time-
5	  
	  
mated with male Tabby mice. Wild-type matings served as controls. Around day 18.5 of 
gestation, the cages were checked daily for new litters. The day of birth is defined as day P0 
and the litter size was recorded. The pups were weighed daily and their size was measured 
at P0, P10 and P20. The sex was recorded at day 17. When wild-type and Tabby litters were 
born on the same day, a litter exchange (with about half of the litter) was done. According to 
the age at analysis, P0, P21, P42 or lactating day 1 (L1), the mice were sacrificed by 
decapitation (P0) or cervical dislocation (other time points) and inguinal mammary glands 
were harvested as described elsewhere [23]. For macroscopic analysis of nipple 
development, digital close-up pictures were taken and scored (i.e. 1, flat nipple; 2, cubical 
form; 3, cylindrical shape). Representative examples are displayed in Supplementary Figure 
2. 
 
Carmine Alum Staining 
For whole mount analysis the 4th inguinal glands were spread on glass slides, fixed overnight 
in glacial acetic acid/ethanol (2:8, v/v), rehydrated through descending alcohol series, and 
stained with carmine alum (Sigma-Aldrich, Taufkirchen, Germany) overnight. Stained tissues 
were dehydrated and soaked with BABB (Benzylalcohol : Benzylbenzoate 1:2; Sigma-
Aldrich). Whole mount mammary glands were subsequently investigated using a Leica 
stereomicroscope MZ 10F (Leica Microsystems, Wetzlar, Germany) with Zeiss Axiocam Typ 
MRc and Axiovision 4.7 software (Carl Zeiss Microscopy GmbH, Göttingen, Germany). 
Quantification of the fat pad area filled by ducts was performed via ImageJ software [24] as 
described elsewhere [25]. The peripheries of the gland and of the ductal tree were contoured 
manually and the respective pixel areas were recorded digitally. The ratio of these two areas 
(Fig. 4 d-f) represents the percentage of fat pad area filled by ducts.  
 
Immunohistochemistry 
Mammary tissues of untreated or Fc-EDA-treated Tabby and wild-type female mice were 
fixed in 4% PFA overnight, embedded in paraffin, and cut into 5-µm sections. Dewaxed and 
rehydrated sections were stained with hematoxylin-eosin for quantification of the epithelial 
content. To prepare sections for immunofluorescence staining they were heated in a 
microwave oven (650W) for 15 minutes in sodium citrate buffer (pH 9.0 for ZO-1, occludin, E-
cadherin, PCNA; pH 6.0 for Krt14, SMA, except for the fluorescent milk proteins staining 
where no antigen retrieval was required). Sections were blocked using 10% normal goat 
serum in protein block solution (DAKO, Hamburg, Germany) and incubated overnight with 
primary rabbit antibodies against ZO-1 and occludin (1:50 and 1:100, respectively; Thermo 
Fisher, Schwerte, Germany) or Keratin 14 (1:50; Biolegend, Koblenz, Germany), mouse 
antibodies against SMA (1:500; Sigma-Aldrich), PCNA (1:200; DAKO Hamburg, Germany) or 
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E-cadherin-FITC (1:100; BD Bioscience, Heidelberg, Germany) and rabbit anti-milk serum 
(1:5000; Accurate Chemical, Westbury, USA), followed by secondary Alexa fluor 594-
labelled goat anti-rabbit or anti-mouse (1:500; Thermo Fisher) or Alexa fluor 488-labelled 
goat anti-mouse (1:500; Thermo Fisher) antibodies, diluted in blocking solution. Sections 
were analyzed using the Axiovert 200M microscope and the AxioVision software (Carl Zeiss 
Microscopy GmbH). Quantification was performed with ImageJ software [24]. The number of 
epithelial PCNA-positive cell nuclei and TUNEL-positive cells was normalized to the total 
number of DAPI-positive cells per duct, respectively. 
 
Sudan III lipid staining 
Lipids in L1 glands were visualized by Sudan III staining. Cryosections were fixed in 4% PFA 
for 30 minutes, washed with 50% ethanol, stained with 0.3% Sudan III solution (Merck 
Millipore, Billerica, Massachusetts, USA) in 70% ethanol for 25 minutes and then washed 
with 50% ethanol. Subsequently, slides were counterstained with hemalum. 
 
Western blotting 
Western blotting was performed according to standard procedures as described previously 
[26]. Snap-frozen 4th inguinal mammary glands at L1 were homogenized and lyzed using cell 
lysis buffer (50 mM Tris pH 7.4, 150 mM Sodium chloride, 1% Nonident P40, 0.25% 
Sodiumdesoxycholat, 1 mM EDTA, 1mM PMSF, 1 mM Sodium fluoride, 1µg/ml Aprotinin, 
Leupeptine, Pepstatin). After centrifugation supernatants were stored at -20°C. Protein 
concentrations were measured using the BCA assay and 20 µg of each sample were 
separated on a 10% SDS gel. Rabbit anti-milk serum (1:1000; Accurate Chemical, Westbury, 
USA) was used as primary antibody, and for loading control rabbit anti-GAPDH, followed by 
HRP-conjugated anti-rabbit antibody (1:500; Cell Signaling Technology, Leiden, The 
Netherlands) as secondary antibody. Amersham ECL Western Blotting detection reagent 
(GE Healthcare Life Sciences, Freiburg, Germany) and the ADVANCED Fluorescence and 
ECL imager (INTAS science imaging, Göttingen, Germany) were used for detection. 
Densitometric estimation of the relative amount of protein normalized to GAPDH was 
performed with ImageJ software [24] as described elsewhere [25]. 
 
RNA isolation and qPCR 
Total RNA from the 4th inguinal mammary glands at L1 was extracted with TRIzol (Thermo 
Fisher) and reverse transcription was performed using the ThermoScript RT-PCR System 
(Thermo Fisher). For real-time PCR with a SYBR-green-based RT-PCR assay on the CFX96 
TouchTM Real-Time PCR Detection System (BioRad, München, Germany), the following 
specific primer sequences were used: EDA_forward) GCAGGCCGTCCTTTCAACG; 
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EDA_reverse CTTCAGAATATGCCTTTTCATCA; E-Cad_forward 
GCAGGCCGTCCTTTCAACG; E-Cad_reverse TCCAAATCCGATACGTGATCTTC; ß-
Actin_forward ATGCTCCCCGGGCTGTAT; ß-Actin_reverse 
TCACCCACATAGGAGTCCTTCTG; ZO-1_forward GAGAAGCTGGATTCCTAA; ZO-
1_reverse TCTCGZGGTTCACTTTTTGCA; SMA_ forward CTGACGGGCAGGTGATCAC; 
SMA_reverse GATGCCCGCTGACTCCAT; K14_forward TGAGAGCCTCAAGGAGGAGC; 
K14_reverse TCTCCACATTGACGTCTCCAC; ß-casein_forward 
GCTGCAGGCAGAGGATGTG; ß-casein _reverse GTTTGAGCCTGAGCATATGGAAA; 
WAP_forward TGTCCCGGTACCTGTGGTA; WAP_reverse GGCAGAAGCCAGCTTTCG; 
Ccdn1_forward ACGCACTTTCTTTCCAGAGTCAT; Ccdn1_reverse 
CTCCAGAAGGGCTTCAATCTGT; Elf5_forward GCTGATTCCAGTTGCTTGAAAAC; 
Elf5_reverse GGGACAGCAGCAAGTCTCTGA; RANKL_forward 
GGTCTAACCCCTGGACATGTG; RANKL_reverse CTTTGCAATGACATGGCATCCT; 
RANK_forward CGAGGAAGATTCCCACAGAG; RANK_reverse 
CAGTGAAGTCACAGCCCTCA; PGR_forward GGTCCCCCTTGCTTGCA; PGR_reverse 
CAGGACCGAGGAAAAAGCAG; PRLR_forward GCAGTGGCTTTGAAGGGTTA; 
PGLR_reverse TGCTAGAGAAGGGCAAGTCTG; ESR1_forward 
TTCGTCCAGCACCTTGAAGTCTCTG, ESR1_reverse 
CATCTCCAGGAGCAGGTCATAGAGG. Gene expression was normalized to E-cadherin 
(epithelial marker [34]) and ß-actin housekeeping genes and analyzed by the comparative 
cycle threshold method (ΔΔCt). 
 
Statistical Analysis 
 
Statistical analysis was performed using the GraphPad Prism software 7 (GraphPad 
Software Inc., La Jolla, USA). Unpaired t-tests were used for the comparison of two samples 
and one-way ANOVA with Bonferroni’s multiple comparison test for multiple samples. Data 
are shown as mean ±SEM, unless stated otherwise.  
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Results 
 
Inadequate weight gain of neonatal Tabby mice depends on the mother 
Due to the lack of EDA protein, the Tabby mouse strain exhibits a phenotype characterized 
by abnormally shaped teeth, missing sweat glands and absence of certain hair types [18, 
27]. In addition, growth restriction is conceived to be a feature of Tabby mice, yet no 
conclusive data have been published so far. Therefore our litters were weighed daily from the 
date of birth (P0) to weaning (P20). After birth, body weights of mice steadily increased for 
more than two weeks and then stabilized between P16 and P18 (Fig. 1a). Hence, P17 was 
chosen to compare the weight of several hundreds of wild-type and Tabby pups (Fig. 1b). 
Although growth and weight gain varied considerably between litters especially in Tabby 
mice (Fig. 1a), the mean weight of Tabby pups was significantly lower (7.0±1.2 g) than that of 
wild-type pups (7.5±1.0 g) at P17 (Fig. 1b). Additionally, the mean weight of pups depended 
on the litter size both in wild-type and Tabby mice: mice from small litters were up to one 
gram heavier than those from large litters (Fig. 1c). No sex-specific weight differences were 
observed at that age (Fig. 1d).  
To elucidate the cause of growth restriction in our animal model, cross-fostering was 
performed. When wild-type and untreated Tabby litters were mixed at P1 and subsequently 
re-distributed to Tabby or wild-type dams, Tabby pups fed by wild-type dams had the same 
mean weight as wild-type pups fed by wild-type dams (Fig. 1e). Furthermore, wild-type pups 
fed by untreated Tabby dams showed the same mean weight as untreated Tabby pups fed 
by untreated Tabby dams (Fig. 1e). These results indicate that the postnatal growth 
restriction of untreated Tabby pups is a result of EDA-deficiency in mothers, but not in the 
pups themselves.  
 
Corrected nipple anatomy in Tabby females following prenatal treatment with Fc-EDA  
The mammary gland is composed of a complex ductal tree that converges into a central duct 
at the nipple. During pregnancy, nipples undergo changes in size and architecture. During 
the first half of pregnancy nipples acquire a conical shape, in the second half (days 15 to 18 
in the mouse) their size increases [28]. Nipple shape and functionality are important 
prerequisites for breastfeeding. Macroscopic comparison of native Tabby and wild-type 
nipples on day 1 of lactation (L1) with a scoring system revealed that the nipples of untreated 
Tabby mice had significant morphological deficits (Fig. 2a, d) when compared with treated 
Tabby mice or wild-type dams (p<0.05 and p<0.01, respectively). Their nipples appeared 
smaller and flattened rather than cylindrical as in wild-type animals (Fig. 2c, d). Nevertheless, 
the pups of untreated Tabby dams were able to suckle after birth. Prenatal treatment with Fc-
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EDA on E15 increased the height and tapering of nipples in adult Tabby mice (Fig. 2b, d) 
towards those of wild-type mice (Fig. 2c, d).  
 
Improved breastfeeding ability and behavior of Tabby mice treated with Fc-EDA 
Next, we investigated whether prenatal treatment with Fc-EDA would improve the maternal 
breastfeeding capacity during the phase of lactation in later life, comparing the weight of 
pups from Fc-EDA-treated and control mothers (Fig. 3a-c). The body lengths of these pups 
were measured at P0, P10 and P20. The sex was determined at P17. Breastfeeding was 
analyzed in litters of defined size (5–7 pups) and was compared between Fc-EDA-treated 
Tabby mothers, untreated Tabby and wild-type mice (Fig. 3a). While all three groups had 
similar birth weights and BMI (not shown), the pups of Fc-EDA-treated mothers gained 
significantly more weight (p<0.001) when breastfed than pups of untreated mothers (Fig. 3b). 
As a consequence, the pups of Fc-EDA-treated mothers were significantly heavier (11%, 
p<0.001) than pups of untreated mothers at P20 (Fig. 3a). Pups of Fc-EDA-treated mothers 
also showed a significantly higher BMI at P10 (Fig. 3b) but similar longitudinal growth. In 
none of the groups, sex-linked weight differences were observed at birth or at P17 (Fig. 3c). 
 
Enhanced branching morphogenesis in treated mammary glands during development 
The prenatal administration of Fc-EDA improved branching morphogenesis and ductal 
elongation in Tabby mice when compared with mammary gland development of untreated 
Tabby females (Fig. 4). In Fc-EDA-treated pups, a ductal tree with about 12±1 branches had 
formed in the mammary gland at P0. At the same time point, mammary glands of untreated 
Tabby mice displayed significantly less end tips (6.6±0.5, p<0.05, Fig. 4g) and branch points 
(6.0±0.8 vs. 9.0±2.0, p<0.05, Fig. 4h) in whole mount sections. At the prepubertal stage 
(P21) and during puberty (P42) branching morphogenesis and ductal elongation in Fc-EDA-
treated Tabby mice remained superior to their untreated counterparts (Fig. 4), with a marked 
increase in the number of end tips (4.8±2.0 vs. 15.5±1.5 at P21, p<0.05, Fig. 4g) and branch 
points (7.6±0.8 vs. 13.5±0.5, p<0.05, Fig. 4h) at P21. The effect of Fc-EDA treatment on 
mammary gland branching morphogenesis was evident also at P42 (Fig. 4a-f), when 2.3-fold 
more end tips (56.0±8.0) were found in treated mammary glands (Fig. 4b, e, g) than in 
glands from untreated Tabby mice (24.0±2.5; Fig. 4a, d, g). As elongation of mammary ducts 
in mice takes place as a result of rapid growth of their end buds and depends on branching, 
the number of branching points is considered a valid proxy for the outgrowth of the ducts 
[29]. At P42 we found a ~3-fold increase in the number of branch points when comparing 
untreated with Fc-EDA-treated Tabby mice (14.6±1.8 vs. 42.3±10.7, respectively; p<0.001, 
Fig. 4h). Our whole mount histology additionally showed that mammary glands of untreated 
Tabby mice (Fig. 4a, d, g-i) remained poorly developed throughout the observational period, 
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with a much smaller area of fat pad filled by epithelial structures at P21 (1.4±0.8 vs. 4.5±0.3, 
p< 0.05, Fig. 4d, i) and P42 (8.9±1.5 vs. 25.0±8.3, p< 0.05, Fig. 4d, i) than in wild-type mice. 
 
Significant effects of prenatal Fc-EDA treatment on alveologenesis 
As analysis during puberty indicated a significant effect of Fc-EDA treatment on mammary 
gland branching morphogenesis and pups from untreated Tabby mothers showed slower 
weight gain than pups from Fc-EDA-treated mothers, we further hypothesized that Fc-EDA 
might also have beneficial long-term effects on mammary gland development during alveolo- 
(E14.5 and E18.5) and lactogenesis (L1). At mid-pregnancy alveoli divide and alveolar cells 
form an envelope surrounding the circular lumen. Thus, the epithelial cell number and 
epithelial surface area increase [30]. At the end of pregnancy we observed >20% epithelial 
structures in the mammary fad pad (Fig. 5c, g), compared to ~5% pre-gestationally. 
While epithelial ducts of Tabby mice undergo alveolar switching (Fig. 5a), their extension into 
the mammary fat pad remained insignificant throughout gestation (~12% at all time points 
investigated, Fig. 5g). Interestingly, Fc-EDA treatment increased the gestational alveolar 
growth by up to 27%, so that ~16% of the fat pad were occupied by alveoli (Fig. 5b, g) at L1. 
Treatment with Fc-EDA, however, did not lead to a complete normalization of alveologenesis 
when compared with wild-type mice (Fig. 5c, g). Nevertheless, the improvement was 
sufficient to support the postnatal growth of pups (Fig. 3). 
Reduced expansion of alveoli and the predominance of adipocytes in the mammary glands 
of untreated Tabby mice were clearly evident (Fig. 5a`, b`). The presence of large 
cytoplasmic lipid droplets (CLD) in untreated and Fc-EDA-treated mammary glands could be 
indicative of a secretory dysfunction [31, 32] in these mice (Fig. 5a`, b`). This illustrates that 
treatment with Fc-EDA does not lead to a complete rescue of mammary function, although 
the breastfeeding ability of treated mothers improved (Fig.3). We further investigated whether 
the observed effects of Fc-EDA on the mammary gland were secondary to enhanced 
proliferative or decreased apoptotic activities within epithelial structures. 
Immunofluorescence staining for PCNA (Proliferating Cell Nuclear Antigen) on mammary 
glands at an age of 6 weeks and at L1 revealed a significantly increased proliferation rate of 
epithelial cells at P42 and of alveolar cells at L1 in Fc-EDA-treated dams (Fig. 5d, e, f, h). In 
detail, the epithelial proliferation rate was approximately 40% and 15% higher at P42 and L1, 
respectively, (10.0±1,8 and 16.0±0.91) than in untreated animals (6.0±1.0 and 12.0±0.3). 
Analysis of ductal apoptosis via TUNEL assay showed no significant differences between 
untreated (5.0±0.8 and 2.4±0.3), Fc-EDA-treated (5.0±0.7 and 2.2±0.2) and wild-type 
(4.4±0.9 and 2.3±0.4) mice at the same time points (Fig. 5i), with a generally low percentage 
of TUNEL-positive cells. These findings suggest that the delay in mammary gland 
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development in untreated Tabby mice is at least partly due to reduced proliferation of their 
epithelial ducts.  
To investigate the glandular architecture of secretory alveoli, mammary epithelia from 
untreated, Fc-EDA-treated and wild-type mammary glands, we performed 
immunofluorescence staining for proteins involved in cell-cell junctions (ZO-1, occludin, and 
E-cadherin [33, 34]) (Fig. 6a-c, Supplementary Fig. 3) and mammary basal cell markers 
(keratin 14 [35, 36] and alpha-smooth muscle actin (SMA) [35, 37]) (Fig. 6d-f). Our analysis 
revealed that the apical expression of ZO-1 seemed irregular in the epithelium of Tabby 
mammary glands independent of their Fc-EDA-treatment status (Fig. 6a, b). In contrast, 
marker proteins of glandular cell-cell adherence (E-cadherin, Fig. 6c, d), the major integral 
epithelial tight-junction protein occludin (Supplementary Fig. 3), basal cell structure and 
myoepithelial function of outer glandular cells (keratin 14 and SMA, Fig. 6c-e) were located 
as expected within the gland. The concomitant quantitative RT-PCR (qPCR) analysis of 
these genes showed no significant expression differences (Fig. 6h) between the groups.  
Furthermore, we determined the mRNA expression of Ccdn1 as potential target gene of the 
EDA-NF-κB pathway by qPCR and found a significant reduction both in untreated and Fc-
EDA-treated Tabby mice (Fig. 6h) compared with wild-type mice. A similar expression 
pattern was observed for the transcription factor Elf5 (Fig. 6h), which has an essential role 
during early embryogenesis and mammary gland development as well as during pregnancy 
and lactation [38]. 
 
Impact of Fc-EDA treatment on lactating mammary glands 
Female Tabby mice showed abnormal lactation resulting in significantly reduced weight gain 
of their pups. Therefore, we also investigated the milk composition. Two key components of 
murine milk are ß-casein and whey acidic protein (WAP) [39]. The measurement of the 
respective mRNA expression revealed a significant diminishment of ß-casein mRNA and a 
tendency towards reduced WAP expression in mammary glands from untreated and Fc-
EDA-treated Tabby dams at L1 (Fig. 7a). Western blot analysis using an antibody against 
rabbit anti-milk serum confirmed that untreated and Fc-EDA-treated protein lysates from L1 
mammary glands of Tabby mice tend to contain less milk protein than corresponding wild-
type lysates (Fig. 7b, c).  
Paraffin sections of L1 mammary glands were stained with an antibody against murine milk 
proteins. Less milk protein was present in the acini of lactating mammary glands from Tabby 
dams compared with control animals (Fig. 7c-e). Sudan III staining of cryosections 
highlighted large fat droplets in the alveolar lumina of both treated and untreated Tabby 
mothers (Fig. 7f-h). The fat droplets seemed to coalesce to larger aggregates, which were 
not observed in wild-type glands to the same extent. Taken together, lack of functional EDA 
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protein leads to reduced expression of milk proteins, particularly ß-casein, in luminal cells 
and thus to a different milk composition which was not changed by prenatal treatment with 
Fc-EDA (Fig. 7a, b, d, g). 
 
 
Discussion 
 
Mikkola et al. identified a role of EDA signaling in mammary gland development [40-42]. EDA 
is a unique factor regulating embryonic and prepubertal mammary gland morphogenesis 
through activation of EDAR/NF-κB in the epithelium [7]. In the mouse model, EDA deficiency 
or inhibition of NF-κB led to a reduction of ductal tree size and fewer branching points [7, 43]. 
On the contrary, overexpression of EDA induced a NF-κB-dependent phenotype with 
amplified ductal growth and branching rates due to enhanced epithelial cell proliferation [7, 
42]. 
Our results confirm the previously described EDA action during hormone-independent 
mammary gland morphogenesis. In addition, our data suggest that EDA or the stimulation of 
the EDA/EDAR pathway is also crucial for the hormone-dependent stages of breast 
development during puberty and alveologenesis/lactation. Prenatal treatment with Fc-EDA 
led to a significantly improved branching morphogenesis during puberty in Tabby mice. 
During lactation, untreated Tabby mice showed a significantly impaired breastfeeding 
capacity secondary to reduced mammary gland alveologenesis and nipple malformation as 
well as a reduced expression of milk proteins. As a result, Tabby pups displayed a markedly 
lower weight compared to age-matched wild-type pups. Our mother exchange experiments 
showed that the maternal EDA deficiency was causative for the reduced weight gain in the 
offspring. The observation that litter size affected the weight of pups also suggested that 
reduced availability of maternal milk was relevantly curtailing their growth. Prenatal treatment 
with Fc-EDA partially, yet significantly alleviated these symptoms by normalizing epithelial 
cell proliferation and nipple formation, thereby enabling regular weight gain of the Tabby 
offspring. However, epithelial architecture and milk composition at L1 remained unaffected. 
The latter finding has to be interpreted with caution though, as the reduction in ß-casein and 
WAP mRNA expression could also have resulted from the limited size of the epithelial tree in 
Tabby mammary glands. Nevertheless, a functional defect in the secretory luminal epithelial 
cells seems plausible, since the size of the ductal tree in Fc-EDA-treated glands was almost 
comparable to that of wild-type glands. Noteworthy, besides the dependence on 
mammogenic auto-/paracrine signals [44, 45] and on epithelial-stromal/extracellular matrix 
interactions, mammary epithelial cell (MEC) proliferation does strongly rely on cell-cell 
contacts within the end bud [46]. Perturbations that disrupt end-bud integrity inhibit ductal 
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extension. Normal epithelial cell-cell contacts are vital for growth signal transduction (e.g. 
from estrogen and GH) [46]. While mammary ducts and alveoli consist of inner (luminal) 
epithelial cells and outer (basal) myoepithelial cells [17, 47], terminal end buds (TEBs) are 
composed of epithelial cap and luminal body cells. MECs are linked at their cell-cell 
interfaces by tight junctions, adherent junctions and desmosomes [48]. Physiologic 
mammary gland cell architecture is a strong prerequisite for the synthesis and secretion of 
milk. The zona occludens protein (ZO), one of the predominant tight junction proteins, forms 
a continuous band at the apical surface of the luminal epithelial cells [48]. Dislocation of ZO-1 
is linked to disruption of the cell polarity protein complex and leads to a disturbed branching 
morphogenesis and impaired ductal barriers for cyclical changes during lactation [49, 50]. As 
for other molecules important for structural integrity such as E-cadherin [34], SMA [35, 37, 
51] and keratin 14 (K14, [35, 36]), we did not observe a significant change in mRNA 
expression rate of ZO-1 in Tabby mice, nor were we able to identify loss of ductal/TEB 
integrity. However, the apical expression of ZO-1 seemed to be inhomogenously distributed 
among luminal epithelial cells of Tabby glands independent of their Fc-EDA-treatment status 
which might have contributed to the impaired secretory capacity of the luminal MEC in Tabby 
mammary glands. Interestingly, ZO-1 expression has been shown to be regulated by NF-κB 
in the epithelium of the intestine [52]. On the contrary, the epithelial distribution of occludin, 
an integral transmembrane tight junction protein, appeared homogenous. Thus, a potential 
involvement of ZO-1 in the decreased breastfeeding capacity of Tabby mice remains to be 
investigated by further functional analyses. During pregnancy the nipple increases in size 
both in humans and mice [28]. Similarly to mammary gland tissue, the nipples originate from 
embryonic ectoderm and are hence negatively affected by EDA deficiency. Both human 
female subjects heterozygous for an EDA mutation and female Tabby mice show very flat 
nipples with subsequent breastfeeding problems [11]. The molecular mechanisms of 
embryonic nipple development have been well documented in K14-PTHrP transgenic mice, 
where the human K14 promotor was used to drive the expression of the peptide growth 
factor parathyroid hormone-related protein (PTHrP). The simultaneous stimulation of PTHrP 
is required for the formation of a patch of nipple epidermis [53-55]. Interestingly, PTHrP was 
identified as a putative target gene of the EDA pathway [7]. Therefore it is conceivable that in 
the absence of EDA, PTHrP can no longer be activated by the EDA-NF-κB pathway, 
resulting in impaired nipple development during the embryonic stage and lactation.  
Importance of the NF-κB pathway for EDA function is further suggested by our finding that 
Ccdn1 expression was reduced in Tabby mice. As a potential target gene of the EDA-NF-κB 
pathway [5] and a known co-regulator of the estrogen receptor (ER) during different stages of 
mammary gland development [56], Ccdn1 is a promising candidate gene for EDA-dependent 
regulation of various processes throughout mammary gland development, preferably during 
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the expansion of mammary epithelium during pregnancy. Deletion of Ccdn1 in mice indeed 
leads to an arrest of mammary gland development before the lobulo-alveolar stage [57-59]. 
Unfortunately, intra-amniotic Fc-EDA treatment did not rescue Ccdn1 expression in the 
mammary glands of Tabby mice, which may indicate a permanently diminished estrogen-
response despite Fc-EDA treatment. Further studies are needed to clarify these findings. 
During initiation of lactation and lactogenesis in particular, ductal epithelial cells undergo 
functional differentiation [17], mainly driven by progesterone and prolactin [60, 61] via their 
respective receptors [17, 62]. The exact mechanism of action of these hormones and their 
levels in EDA-deficient mammary glands is still unknown. In the initial phase of lactation 
Ccdn1 is essential for morphogenesis and side-branching of progesterone receptor(PR)-
positive epithelial cells [63], while in the main phase the paracrine action of the TNF family 
member receptor activator of NF-κB-ligand (RANKL) seems to play an important role: Beleut 
et al. were able to show that ablation of RANKL in the mammary epithelium abrogated 
progesterone-induced morphogenesis, while its ectopic expression fully rescued the PR-
deficient phenotype [63]. Similarly, systemic administration of RANKL induced mammary 
epithelial proliferation in the absence of progesterone signaling, and injection of a RANK 
signaling inhibitor interfered with progesterone-induced epithelial proliferation [63]. 
The fact that we did not observe significant differences in the expression of local RANKL, 
RANK, progesterone- and prolactin-receptors (PRLR) between groups in the study 
(Supplementary Fig. 1) argues against a compensatory mechanism in the absence of EDA. 
However, we observed a significant reduction of Elf5 expression during lactation, which 
might suggest an involvement of RANKL at this hormone-dependent stage of mammary 
gland development in Tabby mice. Progesterone drives mammary secretory differentiation 
via RANKL-mediated induction of Elf5 in luminal progenitor cells [64], making it essential for 
early embryogenesis and mammary gland development during pregnancy and lactation [38]. 
Furthermore Elf5 acts downstream of the prolactin receptor to modulate alveolar 
morphogenesis and secretory activity [65]. As Elf5 is a downstream target of the NF-κB 
pathway [43], lack of EDA and subsequently reduced NF-κB signaling might have negatively 
affected the local progesterone and prolactin action via Elf5 in Tabby mice. In line with this 
finding, we observed a tendency of reduced expression of PRLR in Tabby mice regardless of 
treatment, when compared to wild-type animals (Supplementary Fig. 1). Intra-amniotic 
administration of Fc-EDA, however, did not rescue Elf5 expression in the mammary glands of 
Tabby mice, which could argue for a permanently diminished response to the above 
hormones despite effective Fc-EDA treatment. This has to be addressed by future studies. 
 
Our findings are limited by the fact that the local cross-talk of estrogen and progesterone with 
growth factors during day L1 remains unclear. Others have shown, however, that estrogen 
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receptor alpha and E2 are essential to ensure the state of terminal differentiation in 
mammary epithelial cells [66] while progesterone receptor isoforms were undetectable in 
ducts and alveoli at day L10 in mice [67]. Furthermore, our gene expression analysis was 
based on total RNA extracted from mammary gland whole mounts. Therefore, the ratio of 
epithelium to stroma might have varied. Although epithelial and stromal housekeeping genes 
were chosen, future studies with epithelial extracts might be necessary to verify our results. 
We also did not run functional tests to assess tight junction patency, such as analyses of milk 
composition. It thus remains to be clarified, whether a disorganization of ZO-1 may have 
contributed to the impaired breastfeeding behavior of Tabby mice. 
 
Taken together, EDA seems to play roles in embryonic and prepubertal mammary gland 
development [7], but possibly also in post-developmental mammary gland physiology. 
Administration of recombinant EDA during murine embryogenesis has a considerable impact 
on mammary gland morphogenesis. Remarkably, this translates into the improvement of 
several features that develop subsequently, when the recombinant protein is most probably 
no longer present: nipple formation, alveologenesis, and mammary epithelial function during 
puberty and lactation. Our study shows that activation of the EDAR pathway during 
embryonic development of Tabby fetuses improves, but does not fully correct, the mammary 
gland phenotype that is observed when the treated fetuses have reached adulthood. 
Whether recombinant EDA cannot fully recapitulate the action of native endogenous EDA, or 
whether the EDA-EDAR pathway is activated again after embryonic development, e.g. at 
puberty or during pregnancy, will be interesting to investigate in the future. Some of our 
observations have already been confirmed in human HED patients who show similar 
disorders of breast development as Tabby mice [11]. For the affected women, this is of major 
psychological relevance during puberty, adolescence, and especially when breastfeeding.  
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Figure captions  
 
Fig. 1: Growth restriction of newborn Tabby mice depends on the mother 
(a) Weight gain of pups in 32 wild-type (wt) and 24 Tabby litters was recorded daily from birth 
to weaning. The dotted line at P17 indicates the time point used for the analyses shown in 
panels b-e. (b) Weight of native Tabby and wt pups at P17. (c) Weight of Tabby (black bars) 
or wt (striped bars) pups at P17, as a function of litter size. Animal numbers analyzed per 
condition are indicated. Conditions with 4 pups/litter were compared statistically to those of 
smaller or larger litters. (d) Weights of male and female Tabby (black bars) or wt (striped 
bars) pups in litters of 5 to 7 animals. (e) Comparison of the weight of Tabby (Tb) or wt pups 
left with their mothers or transferred at P1 to foster mothers. Black bar: wt pups with Tb 
dams. Grey bar: Tb pups with Tb dams. White striped bar: wt pups with wt dams. Grey 
striped bar: Tb pups with Tb dams. Data are shown as mean ± SD; P-values: ns (p>0.05); 
**(p<0.01); ***(p<0.001). 
 
 
Fig. 2: Nipple development following prenatal treatment with Fc-EDA 
(a-c) Macroscopic comparison of representative nipples from untreated Tabby (a) Fc-EDA-
treated Tabby (b) and wild-type (c) female mice on day 1 of lactation (L1). (d) Semi-
quantitative assessment of the nipple morphology. 1, flat; 2, cubical; 3, cylindrical. Untreated 
nipple score (n=7): 1.57±0.2; Fc-EDA-treated Tabby (n=4): 2.5±0.29; wild-type nipple (n=11): 
2.6±0.15. Data are shown as mean ± SEM; P-values: *(<0.05); **(p<0.01). 
 
 
Fig. 3: Impact of prenatal treatment on breastfeeding efficacy 
(a) Body weight development of pups from untreated Tabby, Fc-EDA-treated Tabby and wild-
type mothers. (b) Body mass index (body weight/body length²) of 10-day-old pups from 
untreated Tabby, Fc-EDA-treated Tabby and wild-type mothers. (c) Weight differences 
between untreated Tabby (black bars), Fc-EDA-treated Tabby (white bars) and wild-type 
pups (striped bars) at P17 were sex-independent. Data are shown as mean ± SEM; P-
values: **(p<0.01); ***(p<0.001), ****(p<0.0001). 
 
 
Fig. 4: Mammary gland whole mount analysis of branching morphogenesis 
(a-f) Carmine-stained whole mounts of representative mammary glands from untreated 
Tabby (a,d), Fc-EDA-treated Tabby (b, e) and wild-type (wt) mice (c, f) at day P42 (Scale 
bar: a-c: 500 µm; d-f: 1 mm) (d-f) In panels d-f, the outer limits of the gland (black dotted line) 
17	  
	  
and the ductal tree (blue lines) are shown. (g) Quantification of end tips as sum of end tips 
and end buds. (h) Comparison of branch point numbers in the three groups. A significantly 
improved structural development of mammary glands was observed in Fc-EDA-treated 
Tabby (white bars) versus Tabby (black bars) female mice at the pre-pubertal stage and 
during puberty (P21 and P42, respectively), which was comparable with that of wild-type 
controls (grey bars). (i) Ductal outgrowth was quantified as percentage of fat pad filled by 
ducts, using the ratio of areas delimited by blue and black dotted lines in panels d-f. Data are 
shown as mean ± SEM; P-values: *(p<0.05); **(p=0.001-0.01); ***(p<0.001).  
 
 
Fig. 5: Effects of prenatal treatment with Fc-EDA on alveologenesis 
(a-c) Carmine-stained whole mounts of representative untreated Tabby, Fc-EDA-treated 
Tabby and wild-type mammary glands on day L1. (d-f, d`-f`) Hematoxylin-eosin-stained 
sections of mammary glands from untreated Tabby, Fc-EDA-treated Tabby and wild-type 
(wt) on day L1, indicating different alveolar densities. (d`-f`) represent higher magnifications 
of the samples shown in panel d-f. (d`, e`) Cytoplasmic lipid droplets in Tabby mammary 
glands are marked by white arrow heads. (g-i) Representative immunofluorescence staining 
for PCNA (red) on day L1. (j) Quantification of the alveolar density prior to gestation (n.l.), on 
days 14.5 and 18.5 of gestation and at L1. (k) Quantification of PCNA-positive nuclei of 
glands from untreated Tabby, Fc-EDA-treated Tabby and wild-type mice at days P42 and L1. 
(l) Quantification of TUNEL-positive cells at days P42 and L1. Scale bar in d: 100 µm. Scale 
bar in d`: 50 µm. Data are shown as mean ± SEM; P-values: **(p=0.001-0.01); ***(p<0.001); 
not significant (p>0.05). 
 
 
Fig. 6: Epithelial cell architecture and expression of NF-κB downstream targets during 
lactation 
(a-c) Immunostaining for the apical cell marker ZO-1 (red) and the cytoskeleton marker E-
cadherin (E-cad, green). Magnified pictures beneath, where the two fluorescent channels are 
shown separately as well as merged, indicate irregular deposition of ZO-1 in Tabby mice 
(white arrowheads in a, b). (d-f) Immunostaining for Keratin 14 (K14, red) and the basal cell 
marker smooth muscle actin (SMA, green). (a-f) Cell nuclei were stained blue with DAPI. (g, 
h) Relative gene expression (quantitative RT-PCR) of the epithelial cell markers stained in a-
f, as well as Ccdn1, Elf5 and EDA in untreated Tabby (black bars), Fc-EDA-treated Tabby 
(white bars) and wild-type (striped bars) mammary gland tissue at day L1. Scale bars in a-d: 
50 µm. Data are shown as mean ± SEM; P-values: (g) not significant (p>0.05); (h) *(p<0.05); 
***(p<0.001); ****(p<0.0001). 
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Fig. 7: No therapeutic effects on epithelial function in the lactating mammary gland 
(a) Relative gene expression of the two milk proteins β-casein and whey acidic protein 
(WAP) in untreated Tabby (black bars), Fc-EDA-treated Tabby (white bars) and wild-type 
mothers’ (striped bars) L1 mammary gland tissue, as measured by quantitative RT-PCR. (b) 
Western blot of milk proteins from mammary gland tissue at L1 (inguinal glands from three 
different females per group). Each lane represents an individual gland from one animal. Non-
lactating (n.l.) mammary glands from adult wild-type female mice were used as control 
tissue. GAPDH served as loading control. (c) Optical densitometric estimation of Casein 
protein level normalized to GAPDH. (d-f) Immunostaining of murine milk proteins in the acini 
of mammary glands at L1 (Scale bar: 50 µm). (g-i) Sudan III staining of cryosections at L1 
revealed large fat droplets in the lumina of alveoli from both untreated and Fc-EDA-treated 
Tabby mice (Scale bar: 100 µm). Data are shown as mean ±SEM; P-values: ns(p>0.05); 
*(p<0.05); **(p=0.001-0.01); ***(p<0.001). 
 
 
Supplement 
 
Supplementary Fig. 1: Hormone-related alterations in Tabby mammary glands. 
Relative gene expression of RANKL, its receptor RANK, and the hormone receptors for 
progesterone (PGR), estrogen (ESR1) and prolactin (PRLR) in Tabby (black bars), Fc-EDA-
treated Tabby (white bars) and wild-type (striped bars) mammary gland tissue at day L1, as 
measured by quantitative RT-PCR. Data are shown as mean ± SEM; P-values: not 
significant (p>0.05). 
 
Supplementary  Fig. 2: Nipple morphology scores. 
Representative example of (a) flat (score 1) (b) cubical (score 2) and (c) cylindrical nipples 
(score 3) of female mice on day 1 of lactation (L1).  
 
Supplementary Fig. S3: Epithelial tight junction barrier.  
(a-c) Immunostaining for the tight junction protein occludin (red) in mammary glands from 
untreated Tabby, Fc-EDA-treated Tabby and wild-type mice on day L1. Cell nuclei were 
stained blue with DAPI. The scale bar in a-c represents 50 µm. 
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